Full Breakdown
FDA Elevates Thyroid Tablet Recall to Highest Risk Category
By Drooid · · How we work
Core Event
Vitruvias Therapeutics Inc. voluntarily recalled a single lot of its 30 mg “Thyroid Tablets, USP” after testing showed the tablets could be superpotent—containing more active hormone than labeled. The U.S. Food and Drug Administration (FDA) subsequently classified the recall as a Class I event, the agency’s most serious category, indicating that use of the product could cause severe health effects or death.
Data & Statistics
- The affected product is identified by National Drug Code 69680-166-00, lot 504950, with an expiration date of September 2026.
- Approximately 1,900 bottles were sold from a batch of about 3,600 units.
- The recall covers 1,955 half-grain (30 mg) tablets packaged in 100-count bottles.
- Each tablet is labeled to contain 19 µg levothyroxine (T4) and 4.5 µg liothyronine (T3).
Official Statements & Responses
The FDA’s Center for Drug Evaluation and Research announced the Class I classification in late September, noting that exposure to the superpotent tablets could lead to serious adverse health consequences, particularly for patients with heart conditions or heightened sensitivity to thyroid hormones. Vitruvias Therapeutics confirmed that the recall was initiated voluntarily, without a formal FDA mandate, and that the company had not received any reports of adverse events linked to the affected lot at the time of the announcement. The firm provided contact information for consumers seeking further assistance.
Consumer Guidance
Patients currently taking the recalled tablets are advised to stop use immediately and consult their healthcare provider before making any changes to their medication regimen. Vitruvias Therapeutics has distributed letters to consignees and the public, and consumers may reach the company by email or phone for additional information.
Background & Context
Class I recalls represent the highest level of risk under FDA regulations and are reserved for products that could cause serious health outcomes or death. Voluntary recalls, such as this one, occur when a manufacturer elects to remove a product from the market without a direct FDA order, though the agency still classifies the severity based on the potential hazard.